Key PointsBristol Myers Squibb’s Growth Portfolio of newer drugs grew 12% to $7.7 billion in the third quarter, supplying nearly all of the company’s 7% revenue gain to $13.1 billion.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.